Antonin De Fougerolles

Dr. Antonin (Tony) de Fougerolles is CEO of Evox Therapeutics, who is developing exosome-based therapeutics to treat a number of life-threatening rare diseases. Tony has over 20 years of biotech R&D experience in building out drug pipelines, and he has played a key role in developing and successfully advancing 3 new drug classes to the market (mRNA, RNAi, single domain antibodies) and in helping build several multi-billion dollar companies from early start-up stage with a handful of employees.

Prior to Evox, Tony was CSO of Ablynx, where he led the company’s non-clinical R&D operations of 400+ employees and played a key role in the approval of the 1st single domain antibody drug, caplacizumab. Prior to Ablynx, Tony was the founding CSO at Moderna Therapeutics and pioneered modified mRNA as a new therapeutic modality for both rare diseases and as vaccines, including initiating and overseeing the early foundational mRNA chemistry and formulation work used in the covid-19 vaccine. Prior to Moderna, Tony was CSO of antibody-based immuno-oncology company Tolerx Inc, and prior to that VP Research at Alnylam where he helped develop RNAi as a new therapeutic modality, including overseeing the development of the 1st approved RNAi delivery system and several now approved RNAi drugs including inclisiran.

Tony has raised over $140m in venture financing, been Principal Investigator on over $80m in grants, has over 60 scientific publications, and is an inventor on over 100 issued U.S. patents. He also currently serves on the Scientific Advisory Boards of MiNA Therapeutics and LIfT BioSciences. Tony received his Ph.D. in Immunology from Harvard University.